The use of PARP inhibitor olaparib in conjunction with temozolomide may be an
effective treatment for patients with advanced uterine leiomyosarcoma whose
tumors harbor a BRCA-like phenotype.
An expert discusses the implications of a subgroup analysis of the
DESTINY-BREAST03 trial, which highlighted the efficacy of trastuzumab deruxtecan
in HER2-positive metastatic breast cancer.